Close menu




October 30th, 2020 | 09:37 CET

BioNTech, Newlox Gold, NEL ASA - get in now!

  • Investments
Photo credits: pixabay.com

Germany in a state of shock! After the announcement of a second lockdown and a steadily increasing number of infections, the calls for a vaccine against coronavirus are getting louder and louder. The question is not when, but how quickly it will be available, especially for risk groups. Three Companies are currently heading for the home stretch. The first mover will not only get fame and recognition, but the market value of the Company will go through the roof. After the strong sell-off on the world's stock markets, there are lucrative entry opportunities.

time to read: 2 minutes | Author: Stefan Feulner
ISIN: CA65151R1001 , US09075V1026 , NO0010081235

Table of contents:


    BioNTech in the pole position

    The British Times reported on Wednesday, citing government circles, that the Mainz-based BioNTech could distribute a vaccine before Christmas. This outcome would enable BioNTech and its partner, Pfizer, to outdo the tough competition from the British Company, Astra Zeneca and the US Company, Moderna. Even if it is "only" a lead of two weeks, this will correlate with the assumed positive study results.

    Pfizer boss sticks to schedule

    Albert Bourda, CEO of Pfizer, recently announced that the Company would apply for emergency approval of its corona vaccine in the United States in November. The FDA approval is conditional on efficacy and safety data being positive in ongoing trials. The US biotech company, Moderna, does not intend to apply for emergency approval until December. After the positive news, BioNTech's share price rose yesterday by over 8% to USD 84.00. The shares were trading at USD 76.00 the day before due to strong selling in the overall market. The high was USD 94.00. If the results remain positive, new highs may only be a matter of time.

    The Green Gold

    First Mover status has already been achieved by Canadian junior gold production and environmental Company, Newlox Gold Ventures Corp., in the area of sustainably mined gold. The strategy was born by chance. "We were shocked when the results came back from the lab showing that the tailings had a higher grade than the mine plan we were developing at the time..." CEO Ryan Jackson told us in an interview. The reason for the high grade in the tailings was due to decades of artisanal processing, which is only 40% effective in extracting gold.

    New focal points set new standards

    Newlox Gold, in collaboration with the Norman B. Keevil Institute of Mining Engineering at the University of British Columbia, has developed a customized system for recovering precious metals from artisanal tailings piles, while at the same time carrying out environmental remediation. Artisanal gold accounts for 20% of global gold production. It is a USD 27 billion industry that has been completely neglected by traditional mining companies. The current market capitalization is just CAD 15 million. Newlox has access to 30 historic, prospective gold projects. The fact that Canadians are paying attention to environmental and social aspects is setting new standards, especially in the gold mining industry.

    Disappointing stock market debut

    The Norwegian hydrogen Company, NEL ASA, is not doing well with partnerships and participations at the moment. The disaster around Nikola, a US fuel cell and battery truck builder, which has been burdened with severe fraud allegations, was already one of the main topics on the capital market this summer. Yesterday came the next, admittedly minor disappointment. The Danish hydrogen Company, Everfuel, celebrated its IPO. NEL ASA still holds 19.9% of the Company, which was spun off in 2019. The placement price was still at NOK 22. However, during the meeting, the price dropped to as low as NOK 15. Considering that hydrogen shares are all the rage at the moment, a bitter disappointment. On the positive side, the Danes were able to place shares worth almost NOK 27 million in a private placement for NOK 22.


    Conflict of interest

    Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") may in the future hold shares or other financial instruments of the mentioned companies or will bet on rising or falling on rising or falling prices and therefore a conflict of interest may arise in the future. conflict of interest may arise in the future. The Relevant Persons reserve the shares or other financial instruments of the company at any time (hereinafter referred to as the company at any time (hereinafter referred to as a "Transaction"). "Transaction"). Transactions may under certain circumstances influence the respective price of the shares or other financial instruments of the of the Company.

    Furthermore, Apaton Finance GmbH reserves the right to enter into future relationships with the company or with third parties in relation to reports on the company. with regard to reports on the company, which are published within the scope of the Apaton Finance GmbH as well as in the social media, on partner sites or in e-mails, on partner sites or in e-mails. The above references to existing conflicts of interest apply apply to all types and forms of publication used by Apaton Finance GmbH uses for publications on companies.

    Risk notice

    Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and etc. on news.financial. These contents serve information for readers and does not constitute a call to action or recommendations, neither explicitly nor implicitly. implicitly, they are to be understood as an assurance of possible price be understood. The contents do not replace individual professional investment advice and do not constitute an offer to sell the share(s) offer to sell the share(s) or other financial instrument(s) in question, nor is it an nor an invitation to buy or sell such.

    The content is expressly not a financial analysis, but rather financial analysis, but rather journalistic or advertising texts. Readers or users who make investment decisions or carry out transactions on the basis decisions or transactions on the basis of the information provided here act completely at their own risk. There is no contractual relationship between between Apaton Finance GmbH and its readers or the users of its offers. users of its offers, as our information only refers to the company and not to the company, but not to the investment decision of the reader or user. or user.

    The acquisition of financial instruments entails high risks that can lead to the total loss of the capital invested. The information published by Apaton Finance GmbH and its authors are based on careful research on careful research, nevertheless no liability for financial losses financial losses or a content guarantee for topicality, correctness, adequacy and completeness of the contents offered here. contents offered here. Please also note our Terms of use.


    Der Autor

    Stefan Feulner

    Stefan Feulner

    The native Franconian has more than 20 years of stock exchange experience and a broadly diversified network.
    He is passionate about analyzing a wide variety of business models and investigating new trends.

    About the author



    Related comments:

    Commented by Carsten Mainitz on October 14th, 2026 | 05:30 CEST

    Tungsten, Weapons and Growth: Almonty, Rheinmetall and Deutz Under Review. Is This an Opportunity in a Megatrend?

    • Tungsten
    • Raw materials
    • Critical raw materials
    • Geopolitics
    • Defence industry
    • Armaments
    • Military
    • Supply chains
    • Investments

    The stock market is not linear. Greed and fear, excessive optimism or excessive scepticism—all of these drive markets. Only the future will tell what is cheap or expensive today. The stocks mentioned above are at precisely this point. Secure supply chains, access to raw materials and defence readiness are high on the agenda of Western governments. These long-term trends play strongly into the hands of defence companies and raw material producers. Almonty, in particular, as a producer of the critical raw material tungsten, holds a leading position in the sector. Where do the greatest opportunities lie for investors now?

    Read

    Commented by Carsten Mainitz on October 14th, 2026 | 05:25 CEST

    Who Profits When Patents Expire? The Billion-Euro Race Between Formycon, Fresenius and Pfizer

    • Biosimilar
    • FDA
    • Milestone
    • Cancer therapy
    • Pharma
    • Patents
    • Investments

    When patent protection for high-revenue biopharmaceuticals expires, a billion-euro market for follow-on products emerges. Michael Sen, head of the German healthcare group Fresenius SE, cites an impressive figure. By 2035, this could generate around EUR 180 billion in revenue. In particular, biosimilars, biotechnologically produced follow-on medicines that are highly similar in composition to the original medicine and equivalent in quality, efficacy and safety, are forecast to grow significantly. Moreover, biosimilars can strengthen competition and reduce treatment costs. Formycon stands out as a pure play. The company recently reached a crucial milestone. The US Food and Drug Administration (FDA) accepted the marketing authorisation application, the first publicly known application of its kind, for FYB206, a biosimilar candidate to the cancer medicine Keytruda, for review. Keytruda generates around USD 32 billion in annual revenue, making it the world's highest-revenue medicine. Fresenius is strengthening its positioning in the biosimilar sector through an acquisition. Pfizer needs new growth drivers. Who is best positioned for the year-end rally?

    Read

    Commented by Matthias Schomber on October 12th, 2026 | 05:24 CEST

    Every Crisis Creates an Opportunity: Nordex Stumbles, Jungheinrich Struggles, and RE Royalties Looks to Have Found a Bottom

    • Investments
    • Trading Opportunity
    • Technical Analysis
    • Rebound

    When market participants suddenly lose their nerve, and industrial heavyweights like Jungheinrich plunge to new multi-year lows despite bulging order books, a key question for private investors, among others, is whether this is a dangerous crisis with further downside ahead or an attractive entry opportunity. Nordex, too, has recently struggled to build on its successes from earlier this year. The share is trapped in a consolidation phase and has now returned to its level from late February, when it broke out upwards on high volume and with a long green weekly candlestick. Is this an attractive entry point for investors desperately seeking stable, high-yield alternatives in the future-oriented renewable energy market? Find out why scepticism could prevail regarding well-known German names and why a pioneer in royalty financing could be on the verge of the next major share price surge following a technical “textbook pattern”.

    Read